BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/5/2026 3:16:56 AM | Browse: 3 | Download: 0
Publication Name World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID 118130
Country United States
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Cohort Study
Article Title Metabolic dysfunction–associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes
Manuscript Source Invited Manuscript
All Author List Rishi Chowdhary, Geng-Qing Song, Manjeet Kumar Goyal, Ashita Rukmini Vuthaluru, Kirti Arora, Rahul Chowdhary, Megh Patel, Akash Batta, Thai-Hau Koo, Venkata Sunkesula, Rohit Goyal and Omesh Goyal
Funding Agency and Grant Number
Corresponding Author Manjeet Kumar Goyal, Department of Internal Medicine, Cleveland Clinic Akron General Hospital, Akron, Ohio, USA, 1, Akron General Avenue, AKron, Akron, OH 44308, United States. manjeetgoyal@gmail.com
Key Words Sleep-disordered breathing; Metabolic syndrome; TriNetX; Cirrhosis; Liver fibrosis; Intermittent hypoxia; Obstructive sleep apnea; Metabolic dysfunction-associated steatotic liver disease
Core Tip Metabolic dysfunction-associated steatotic liver disease (MASLD) and obstructive sleep apnea (OSA) often coexist due to shared risk factors. Furthermore, OSA can lead to liver complications. In this large multicenter study, patients with MASLD had a significantly higher prevalence of OSA and an earlier onset of OSA. Coexisting OSA markedly increased the long-term risk of developing hepatic fibrosis and cirrhosis. These findings highlight the importance of routine OSA screening in patients with MASLD and support integrated metabolic and sleep-focused management to prevent hepatic disease progression.
Citation Chowdhary Ri, Song GQ, Goyal MK, Vuthaluru AR, Arora K, Chowdhary Ra, Patel M, Batta A, Koo TH, Sunkesula V, Goyal R, Goyal O. Metabolic dysfunction–associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes. World J Gastrointest Pharmacol Ther 2026; In press
Received
2025-12-24 03:42
Peer-Review Started
2025-12-24 03:43
First Decision by Editorial Office Director
2025-12-31 08:23
Return for Revision
2025-12-31 08:23
Revised
2026-01-01 17:28
Publication Fee Transferred
Second Decision by Editor
2026-02-04 02:39
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-02-05 03:16
Articles in Press
2026-02-05 03:16
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 2150-5349 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com